These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 27320035)

  • 1. Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous cycles for in vitro fertilization?
    Londra L; Moreau C; Strobino D; Bhasin A; Zhao Y
    Fertil Steril; 2016 Sep; 106(3):666-72. PubMed ID: 27320035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles.
    Chen H; Wang Y; Lyu Q; Ai A; Fu Y; Tian H; Cai R; Hong Q; Chen Q; Shoham Z; Kuang Y
    Fertil Steril; 2015 May; 103(5):1194-1201.e2. PubMed ID: 25813280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential impact of controlled ovarian hyperstimulation on live birth rate in fresh versus frozen embryo transfer cycles: a Society for Assisted Reproductive Technology Clinic Outcome System study.
    Gerber RS; Fazzari M; Kappy M; Cohen A; Galperin S; Lieman H; Jindal S; Buyuk E
    Fertil Steril; 2020 Dec; 114(6):1225-1231. PubMed ID: 33012553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
    Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for ectopic pregnancy in assisted reproductive technology: a 6-year, single-center study.
    Bu Z; Xiong Y; Wang K; Sun Y
    Fertil Steril; 2016 Jul; 106(1):90-94. PubMed ID: 27001382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders.
    Xia M; Zheng J
    BMC Pregnancy Childbirth; 2021 May; 21(1):372. PubMed ID: 33975553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GnRH agonist and GnRH antagonist protocols: comparison of outcomes among good-prognosis patients using national surveillance data.
    Grow D; Kawwass JF; Kulkarni AD; Durant T; Jamieson DJ; Macaluso M
    Reprod Biomed Online; 2014 Sep; 29(3):299-304. PubMed ID: 25043892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ectopic pregnancy after in vitro fertilization: differences between fresh and frozen-thawed cycles.
    Londra L; Moreau C; Strobino D; Garcia J; Zacur H; Zhao Y
    Fertil Steril; 2015 Jul; 104(1):110-8. PubMed ID: 25956363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cycle day, estrogen level, and lead follicle size: analysis of 27,790 in vitro fertilization cycles to determine optimal start criteria for gonadotropin-releasing hormone antagonist.
    Lyttle Schumacher BM; Mersereau JE; Steiner AZ
    Fertil Steril; 2018 Apr; 109(4):633-637. PubMed ID: 29605403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger?
    Connell MT; Patounakis G; Healy MW; DeCherney AH; Devine K; Widra E; Levy MJ; Hill MJ
    Fertil Steril; 2016 Sep; 106(3):584-589.e1. PubMed ID: 27178228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.
    Engmann L; DiLuigi A; Schmidt D; Benadiva C; Maier D; Nulsen J
    Fertil Steril; 2008 Mar; 89(3):554-61. PubMed ID: 17678651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
    Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
    Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy outcomes after controlled ovarian hyperstimulation in women with endometriosis-associated infertility: GnRH-agonist versus GnRH-antagonist.
    Kolanska K; Cohen J; Bendifallah S; Selleret L; Antoine JM; Chabbert-Buffet N; Darai E; d'Argent EM
    J Gynecol Obstet Hum Reprod; 2017 Nov; 46(9):681-686. PubMed ID: 28970135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin-releasing hormone analogue as sole luteal support in antagonist-based assisted reproductive technology cycles.
    Bar Hava I; Blueshtein M; Ganer Herman H; Omer Y; Ben David G
    Fertil Steril; 2017 Jan; 107(1):130-135.e1. PubMed ID: 28228316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.